Summary:
- The article discusses the FDA's Complete Response Letters (CRLs), which are letters sent to drug companies when the FDA decides not to approve a new drug application.
- CRLs outline the specific deficiencies in the application and what the company needs to do to address them before the FDA can approve the drug.
- The article explains that the FDA publishes these CRLs to increase transparency and help the public understand the drug approval process.